

IPO Note

EMCURE PHARMACEUTICALS LTD

Jul 03, 2024







Company Profile

Emcure Pharmaceuticals Limited, founded in 1981, is a leading Indian pharmaceutical company specializing in the development, manufacturing, and global marketing of pharmaceutical products across major therapeutic areas. It ranks 13th in domestic sales and holds the 4th position in market share in its covered markets as of MAT September 2023. Emcure Pharma leads in gynaecology and HIV antiviral therapeutics in India. For the six months ended September 30, 2023, and the full Financial Year 2023, domestic sales contributed 50.84% and 53.16% of total revenue, respectively, with a robust growth rate of 10.80% CAGR from September 2019 to September 2023.

As of September 30, 2023, Emcure Pharma employs 552 scientists across five research facilities in India, holds 201 granted patents, and has submitted over 1,800 documents globally, including 204 in the EU and 133 in Canada. The company operates 13 manufacturing facilities capable of producing various pharmaceutical and biopharmaceutical products. Emcure Pharma's marketing and distribution network in India is supported by more than 5,000 field personnel and includes over 5,000 stockists serviced by 37 carryand-forward agents, ensuring extensive market coverage and efficient distribution.

Business Highlights & Services

Emcure specialize in a diverse range of pharmaceutical products globally, focusing on chronic therapeutic areas like gynecology, cardiovascular, oncology, HIV, neurology, respiratory, and anti-diabetic treatments. It portfolio also includes acute therapies such as anti-infectives, pain management, analgesics, and nutritional supplements. It collaborate with multinational pharmaceutical companies to license their products in India and abroad. Ranked among the top pharmaceutical companies in India, it lead in gynecology and HIV antivirals, with a presence in 19 therapeutic areas and sustained growth across major markets from 2020 to 2024.

Emcure strategy focuses on leveraging their expanding product portfolio within India's growing domestic formulations market, projected to reach ₹2.9 trillion to ₹3.0 trillion by FY 2029. It aim to capitalize on market dynamics by investing in specialty products, extending brand life cycles, and expanding their sales and marketing presence. The goal is to increase market share in key therapeutic areas like gynecology, cardiovascular, and oncology through new product launches and enhanced prescriber outreach. With strategic initiatives to optimize the sales force and expand into rural markets, company is poised to strengthen its leadership position and drive sustainable growth.

It enhancing R&D and manufacturing capabilities to drive growth through differentiated product offerings in domestic and international markets. It aim to achieve greater vertical integration to enhance product quality, supply chain efficiency, and cost effectiveness, while aligning with their ESG goals through sustainable practices. Key investment areas include novel drug delivery systems and biotherapeutics, leveraging technologies like flow chemistry and photo-chemistry to address high-growth therapeutic areas with limited global competition.

Company focuses on leveraging differentiated product platforms across global markets. With over 1,800 filed dossiers, it specialize in chiral molecules, complex chemistry, and advanced injectables like liposomal and lyophilized formulations. Operating in 19 therapeutic areas across 70 countries, it tailor their marketing strategies to fit each market's regulatory, competitive, and size dynamics. It growth plan includes expanding product registrations, enhancing customer reach through direct sales forces or strategic partnerships, and prioritizing technology-driven innovations in complex oral solids, injectables, and biotherapeutics.

Jul 03, 2024

Details of the Issue	
Price Band	₹ 960 - ₹ 1,008
Issue Size	₹ 1,952.03 Cr
Face Value	₹ 10
Bid Lot	14
Listing on	BSE, NSE
Post Issue Mcap	₹ 19,029.89 Cr
Investment Range	₹ 13,440 - ₹ 14,112
Important Indicative Da	ates (2024)
Opening	03 - Jul
Closing	05 - Jul
Basis of Allotment	08 - Jul
Refund Initiation	09 - Jul
Credit to Demat	09 - Jul
Listing Date	10 - Jul
Lead Manager	
Kotak Mahindra Capital	Limited
Axis Capital Limited	
Jefferies India Pvt Limit	ted
J.P Morgan India Pvt Lir	nited
Link Intime India Pvt Li	mited

Offer Details

Offer Siz	e		₹1,9	952.03 Cr	
Fresh Iss	ue		₹ 800		
OFS	OFS		₹ 1,152.03 (
	In Rs	No of St	nares (Mn)	% of	
Туре	Type Cr	Upper	Lower	Issue	
QIB	976	9.68	10.16	50	
NIB	293	2.94	3.05	15	
Retail	683	6.77	7.11	35	
Em- ploy.	-	-	-	-	
Total	1,952	19.36	20.33	100	

Invest Now





Company have historically made strategic acquisitions, such as Tillomed Laboratories in the UK and Marcan in Canada. Recently, it bolstered its presence in Quebec through the acquisition of Mantra in Nov23. Additionally, it have secured exclusive distribution rights for products from Sanofi in India, including brands like Cardace and Clexane. Looking ahead, it plan to pursue further strategic acquisitions and in-license pharmaceutical products to expand in existing and new markets. It also continue to select local partners and establish subsidiaries with dedicated sales teams to efficiently distribute the products globally.

company operate 13 state-of-the-art manufacturing facilities across India, producing a wide range of pharmaceutical and biopharmaceutical products. It capabilities include manufacturing oral solids, liquids, injectables (including liposomal and lyophilized formulations), biotherapeutics, and complex APIs like chiral molecules and iron products. This vertical integration ensures cost-effective production, quality assurance, and protects the intellectual property. It specialize in in-house production of complex injectables, iron products, photochemistry items, chiral molecules, and biotherapeutics."

Brand and Molecule portfolio

Molecule	Therapeutic Area	Number of Peers in India ⁽¹⁾	MAT Financial Year 2024 (₹ in millions)	MAT Financial Year 2024 Market Rank ⁽²⁾	MAT Financial Year 2024 Market Share ⁽³⁾
Ferric	Gynecology	6	2,597.76	1	58.56%
Carboxymaltose					
S-Amlodipine	Cardiovascular	2	1,513.55	1	87.84%
Tenecteplase	Cardiovascular	1	1,165.23	1	85.90%
S-Metoprolol	Cardiovascular	1	1,077.37	1	92.16%
Ibutilide	Cardiovascular	1	2.79	1	100.00%
Treosulfan	Anti-neoplastics	1	0.79	1	100.00%
Ferrous Ascorbate	Gynecology	1	1.93	1	100.00%

	Therapeutic Area	MAT Financial Year 2024 ⁽¹⁾	MAT Financial Year 2024 Market Rank in subgroup ⁽²⁾	MAT Financial Year 2024 Market Share (at subgroup level) ⁽³⁾
		(₹ in millions)		(%)
Orofer-XT	Gynecology	3,688.34	1	50.89%
Bevon	Vitamins, minerals and nutrients	2,211.26	3	10.08%
Zostum	Anti-infectives	1,934.46	1	33.87%
Maxtra	Respiratory	1,397.47	1	34.17%
Orofer FCM	Gynecology	1,310.47	1	29.54%
Orofer-S	Cardiovascular	1,273.78	1	42.17%
Metpure XL	Cardiovascular	974.58	1	83.37%
Feronia XT	Gynecology	940.12	2	14.09%
Spegra	HIV antivirals	927.54	1	100.00%
Orofer XT Plus	Gynecology	901.76	1	59.81%
Exhep	Cardiovascular	825.10	4	10.74%
Eslo	Cardiovascular	741.64	1	43.04%
Viropil	HIV antivirals	678.23	1	93.15%
Elaxim	Cardiovascular	677.76	1	49.96%
Augpen	Anti-infectives	661.49	10	1.98%
Dydrofem	Gynecology	632.35	4	6.76%
Maxtra P	Respiratory	615.21	5	9.41%
Lornit	Gastrointestinal	587.89	2	34.34%
Pause	Blood-related	585.13	2	26.45%
Encicarb	Gynecology	579.74	2	13.07%

Revenue Breakup Details

		For the	Financial Yea	ar ended Mar	ch 31,	
	202	4	202	3	2022	2
	(₹ in millions, except percentages)					
Sales in India	32,148.98	48.28%	31,818.18	53.16%	32,046.66	54.73%
Sales outside India	34,433.53	51.72%	28,039.93	46.84%	26,507.21	45.27%
Europe	14,235.72	21.38%	11,873.26	19.84%	8,968.17	15.32%
North America	9,279.09	13.94%	7,294.21	12.19%	6,794.50	11.60%
Other continents	10,918.72	16.40%	8,872.46	14.81%	10,744.54	18.35%
Revenue from operations	66,582.51	100.00%	59,858.11	100.00%	58,553.87	100.00%






Therapeutic Portfolio


		Covered Market Growth				
	Emcure MAT	IPM MAT	Emcure MAT	IPM MAT		
Therapeutic Area	5-Year CAGR ⁽¹⁾	5-Year CAGR ⁽¹⁾	3-Year CAGR ⁽²⁾	3-Year CAGR ⁽²⁾		
	(%)	(%)	(%)	(%)		
Gynecology	9.94%	11.59%	9.00%	11.85%		
Cardiovascular	5.90%	7.33%	(5.26)%	12.83%		
Anti-infectives	5.26%	5.81%	3.06%	4.86%		
Vitamins, minerals and nutrients	7.47%	11.90%	(1.19)%	8.16%		
HIV antivirals	25.19%	12.57%	11.99%	11.31%		
Respiratory	10.46%	12.10%	11.00%	11.88%		
Gastrointestinal	8.23%	8.25%	7.20%	7.06%		
Pain and analgesics	9.99%	11.18%	13.71%	8.42%		
Blood-related	7.90%	8.46%	8.68%	15.75%		
Oncology/Anti-neoplastics	25.72%	8.48%	34.03%	19.36%		
Anti-diabetic	32.75%	12.78%	22.07%	18.34%		
Hormones	21.17%	2.08%	26.05%	11.58%		
Neurology/CNS	0.83%	4.27%	5.24%	6.12%		
Others ⁽³⁾	(0.72)%	5.75%	13.81%	19.79%		
Total	9.73%	8.60%	6.38%	10.32%		

Industries Outlook


Number of persons aged 65 years or over by geographic region, 2019 and 2050








Review and outlook on Europe market



Review and outlook on Canada market



Peers Comparison

Name of the company	Face Value (₹)	Total Income (₹ Cr)	EPS	NAV (₹)	P/E	RoNW(%)
Emcure Pharmaceutical Ltd	10	6,658	27.5	163	NA	16.87%
Peers Group						
Dr Reddys Lab Ltd	5	28,011	334	1693	17	19.74%
Cipla Ltd	2	25,774	51	330	30	15.43%
Alkem Laboratories Ltd	2	12,668	150	862	33	17.41%
Torrent Pharmaceutical Ltd	5	10,728	48	202	57	24.15%





Companies Competitive Strength :

- Well-placed to Leverage the Position in the Domestic Market.
- Demonstrated Capabilities of Building Brands
- Large, Diversified and Fast-Growing Product Portfolio in International Markets
- Strong R&D Capabilities Driving Differentiated Portfolio of Products
- Extensive and Diversified Manufacturing Capacity
- Highly Qualified, Experienced and Entrepreneurial Management Team and Board

Key Strategies Implemented by Company

- Increase the Market Share in the Domestic Market.
- Continue to Invest in Research & Development and Manufacturing Capabilities to Enhance and Grow the Differentiated Product Portfolio.
- Deepen and Expand the International Presence with a Focused Go-to-Market Approach.
- Pursue Strategic Acquisitions, Partnerships and In-Licensing Arrangements.

Particular (INR in Cr)	FY24	FY23	FY22
Equity Capital	181	181	181
Reserves and Surplus	2771	2320	1807
Net Worth	3122	2650	2114
Revenue	6,658	5,986	5,855
Growth (%)	11%	2%	
EBITDA	1,220	1,175	1,331
EBITDAM (%)	18%	20%	23%
РАТ	528	562	703
PATM (%)	8%	9 %	12%
ROCE (%)	19 %	22%	30%
ROE (%)	17%	21%	33%

Valuations and Recommendation:

- Based on annualized FY24 earnings to post-IPO paid-up equity capital of the company, The issue is priced at a P/E of 36.07X. Thus the issue appears to be fairly priced compared to peers.
- Emcure is a leading pharmaceutical manufacturer known for its diverse portfolio and robust R&D capabilities. Despite recent profitability challenges due to high finance costs, expected improvements post-debt reduction are anticipated. It consistently outpaces industry growth rates with a domestic sales CAGR of 9.73% and export sales CAGR of 19.51%. With a strong focus on chronic therapeutic fields, which constitute 46.22% of total domestic sales, the company leverages its leading market positions (>50% market share in key molecules) to expand into adjacent therapeutic areas. Strategic acquisitions have bolstered its global presence, ensuring resilience through diversified revenue streams and specialized products targeting high-growth markets. Hence, we recommend an "Subscribe" rating for the issue.





Notes

GEPL Capital Pvt. Ltd

Head Office: D-21/22 Dhanraj Mahal, CSM Marg, Colaba, Mumbai 400001

Reg. Office: 922-C, P.J. Towers, Dalal Street, Fort, Mumbai 400001

Research Analyst - Mr. Dibandu Maji | + 022-6618 2689 | Dibandumaji@geplcapital.com

Disclaimer: This report has been prepared by GEPL Capital Private Limited ("GEPL Capital"). GEPL Capital is regulated by the Securities and Exchange Board of India. This report does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy, recommendation or any other content contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. All investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by the recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of GEPL Capital as a result of using different assumptions and criteria. GEPL Capital is under no obligation to update or keep current the information contained herein. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect GEPL Capital's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by GEPL Capital or any other stheirce may yield substantially different results. GEPL Capital makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. Further, GEPL Capital assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Neither GEPL Capital nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. In no event shall GEPL capital be liable for any direct, special indirect or consequential damages, or any other damages of any kind, including but not limited to loss of use, loss of profits, or loss of data, whether in an action in contract, tort (including but not limited to negligence), or otherwise, arising out of or in any way connected with the use of this report or the materials contained in, or accessed through, this report. GEPL Capital and its affiliates and/or their officers, directors and employees may have similar or an opposite position in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). The disclosures contained in the reports produced by GEPL Capital shall be strictly governed by and construed in accordance with Indian law. GEPL Capital specifically prohibits the redistribution of this material in whole or in part without the written permission of GEPL Capital and GEPL Capital accepts no liability whatsoever for the actions of third parties in this regard.